Skip to Main Content

++

INTRODUCTION

++

eszopiclone (es-zop-i-klone)

Lunesta

Classification

Therapeutic: sedative/hypnotics

Pharmacologic: cyclopyrrolones

Schedule IV

++
Indications
++

Insomnia.

++
Action
++

Interacts with gamma-aminobutyric acid (GABA)–receptor complexes; not a benzodiazepine. Therapeutic Effects: Improved sleep with decreased latency and increased maintenance of sleep.

++
Adverse Reactions/Side Effects
++

CNS: abnormal thinking, behavior changes, depression, hallucinations, headache, sleep-driving. CV: chest pain, peripheral edema. GI: dry mouth, unpleasant taste. Derm: rash.

++

PHYSICAL THERAPY IMPLICATIONS

++
Examination and Evaluation
++

  • Monitor and report daytime drowsiness, depression, behavior changes, hallucinations, and “drugged” feelings. Repeated or excessive symptoms may require change in dose or medication.

  • Assess peripheral edema using girth measurements, volume displacement, and measurement of pitting edema (See Appendix N). Report increased swelling in feet and ankles or a sudden increase in body weight due to fluid retention.

  • Monitor any chest pain and attempt to determine if pain is drug induced or caused by cardiovascular dysfunction (e.g., angina that occurs during exercise).

++
Interventions
++

  • Guard against falls and trauma (hip fractures, head injury, and so forth). Implement fall-prevention strategies, especially in older adults or if drowsiness and dizziness carry over into the daytime (See Appendix E).

  • Help patient explore non pharmacologic methods to improve sleep, including relaxation techniques, regular exercise, avoiding caffeine, and so forth.

++
Patient/Client-Related Instruction
++

  • Instruct patients on prolonged treatment not to discontinue medication without consulting a health care professional. Long-term use can cause tolerance and physical/psychologic dependence, and abrupt withdrawal after 2 or more weeks of use may cause increased sleep loss (rebound insomnia).

  • Advise patient about the risk of daytime drowsiness and decreased attention and mental focus. Use care if driving or in other activities that require strong concentration.

  • Caution patient and family/caregivers that “sleepwalking” and other complex activities including driving a car (sleep-driving) may occur while completely asleep. Care should be taken to monitor such activities and prevent access to motor vehicles while under the influence of this drug.

  • Advise patient to avoid alcohol and other CNS depressants because of the increased risk of sedation and adverse effects.

  • Instruct patient and family/caregivers to report other troublesome side effects such as severe or prolonged skin rash, abnormal thoughts, dry mouth, or unpleasant taste.

++
Pharmacokinetics
++

Absorption: Rapidly absorbed after oral administration.

++

Distribution: Unknown.

++

Metabolism and Excretion: Extensively metabolized by the liver (CYP3A4 and CYP2E1 enzyme systems); metabolites are renally excreted, <10% excreted unchanged in urine.

++

Half-life: 6 hr.

++

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print

TIME/ACTION PROFILE (blood levels)

ROUTE ONSET PEAK DURATION
PO rapid 1 hr 6 hr

++
Contraindications/Precautions
++

Contraindicated in: No known contraindications.

++

Use Cautiously in:...

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.

Ok

About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.